Telloni Stacy M
Duke Cancer Institute, 4101 Macon Pond Road, Raleigh, NC, 27607, USA.
Methods Mol Biol. 2017;1606:1-17. doi: 10.1007/978-1-4939-6990-6_1.
Cancer staging and grading are used to predict the clinical behavior of malignancies, establish appropriate therapies, and facilitate exchange of precise information between clinicians. The internationally accepted criterion for cancer staging, the tumor-node-metastasis (TNM) system, includes: (1) tumor size and local growth (T), (2) extent of lymph node metastases (N), and (3) occurrence of distant metastases (M). Clinical stage is established before initiation of therapy and is determined by physical examination, laboratory findings, and imaging studies. Pathologic stage is determined following surgical exploration of disease and histologic examination of tissue. The TNM classification system has evolved over 70 years to accommodate increasing knowledge about cancer biology. Molecular technologies such as genomic and proteomic profiling of tumors could eventually be incorporated into the TNM staging system. This chapter describes the current TNM system using breast, lung, ovarian, and prostate cancer examples.
癌症分期和分级用于预测恶性肿瘤的临床行为、确定合适的治疗方法,并促进临床医生之间准确信息的交流。国际公认的癌症分期标准,即肿瘤-淋巴结-转移(TNM)系统,包括:(1)肿瘤大小和局部生长情况(T),(2)淋巴结转移范围(N),以及(3)远处转移情况(M)。临床分期在治疗开始前确定,通过体格检查、实验室检查结果和影像学检查来判定。病理分期在对疾病进行手术探查和组织学检查后确定。TNM分类系统已经发展了70多年,以适应对癌症生物学不断增加的认识。诸如肿瘤基因组和蛋白质组分析等分子技术最终可能会纳入TNM分期系统。本章以乳腺癌、肺癌、卵巢癌和前列腺癌为例介绍当前的TNM系统。